Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease

NCT07258641 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Ulcerative Colitis (UC)
Crohn Disease (CD)

Interventions

DRUG: 25mg adalimumab-680LT and 15/25 mg risankizumab-800CW
DRUG: Adalimumab-680LT 25mg
DRUG: Risankizumab-800CW 15 mg/25 mg

Sponsor

University Medical Center Groningen